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Abstract
Background: Body mass index (BMI) has been implicated as a primary factor influencing cancer development.
However, understanding the relationship between these two complex traits has been confounded by both
environmental and genetic heterogeneity.
Methods: In order to gain insight into the genetic factors linking BMI and cancer, we performed chemical
carcinogenesis on a genetically heterogeneous cohort of interspecific backcross mice ((Mus Spretus × FVB/N)
F1 × FVB/N). Using this cohort, we performed quantitative trait loci (QTL) analysis to identify regions linked to BMI.
We then performed an integrated analysis incorporating gene expression, sequence comparison between strains,
and gene expression network analysis to identify candidate genes influencing both tumor development and BMI.
Results: Analysis of QTL linked to tumorigenesis and BMI identified several loci associated with both phenotypes.
Exploring these loci in greater detail revealed a novel relationship between the Pannexin 3 gene (Panx3) and
both BMI and tumorigenesis. Panx3 is positively associated with BMI and is strongly tied to a lipid metabolism
gene expression network. Pre-treatment Panx3 gene expression levels in normal skin are associated with tumor
susceptibility and inhibition of Panx function strongly influences inflammation.
Conclusions: These studies have identified several genetic loci that influence both BMI and carcinogenesis and
implicate Panx3 as a candidate gene that links these phenotypes through its effects on inflammation and lipid
metabolism.
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Background
Elevated body mass index (BMI) has recently been
highlighted as playing a profound role in the develop-
ment of a diverse array of cancers. For some cancers,
such as esophageal, endometrial, and uterine, BMI has
been demonstrated to be associated with up to 40 % of
all cases [1, 2]. In the USA, it is estimated that elevated
BMI and obesity led to the development of 84,500
avoidable cancer cases and as many as 90,000 cancer
deaths annually [1, 3].
A variety of hypotheses have been put forth to explain
the increase in cancer risk associated with elevated BMI,
including systemic inflammation concomitant with obes-
ity, altered growth factor signaling and production, and
altered sex hormone signaling and production [4–6].
The specific mechanism is likely to be dependent on the
cancer type and it is probable that multiple factors
cooperate to enhance cancer risk. Unfortunately, examin-
ing in detail the relationship between these two complex
traits has been confounded by a combination of genetic
complexity and the diverse environmental influences that
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must be taken into account. In order to address this
paucity of data, we have analyzed the relationship between
BMI and cancer incidence in a genetically heterogeneous
mouse population. By crossing tumor susceptible Mus
musculus (FVB) mice with tumor resistant Mus spretus
(SPRET) mice we developed a genetically heterogeneous
cohort of F1 backcross mice that varies significantly in
both tumor susceptibility and BMI. Critically, this cohort
was generated without using engineered susceptibilities to
either obesity or tumorigenesis. This allows us to model
more accurately the human condition of genetic hetero-
geneity and environmental (rather than genetic) tumor
induction.
Using this cohort, we induced skin tumors using
the chemical carcinogen 7,12-Dimethylbenz(a)anthracene
(DMBA) and the tumor promoting agent 12-O-
Tetradecanoylphorbol-13-acetate (TPA) [7]. This proto-
col initially results in the formation of benign papillomas,
a fraction of which will progress into carcinomas. Previous
studies have demonstrated that the tumors produced by
this protocol are profoundly influenced by inherited
susceptibility loci [8–12].
Comparing BMI and tumor burden in this cohort
revealed a significant positive association in male mice.
Using a systems approach involving QTL mapping, gene
expression analysis, and gene expression correlation
network analysis, we have been able to identify several
candidate regions associated with both BMI and cancer.
Further analysis of these regions identified Pannexin 3
(Panx3) as a strong candidate gene for the BMI/tumor
susceptibility locus on chromosome 9. Panx3 expres-
sion levels in normal skin are strongly associated with
BMI and are also correlated with a number of genes
within a well-conserved lipid metabolism network that
may underlie effects on BMI. Panx3 expression is also as-
sociated with tumor development and we demonstrate
that inhibition of Pannexin function causes alterations in
TPA-induced inflammatory signaling, providing a plaus-
ible mechanism for the relationship between Panx3 and
tumorigenesis.
Methods
Mouse breeding and husbandry
Male Mus spretus (SPRET/Ei) and female Mus musculus
(FVB/N) mice obtained from the Jackson Laboratory
were crossed to generate F1 hybrids. Female F1 mice
were then crossed to male FVB/N mice to generate
backcrossed mice, referred to as FVBBX mice. For mice
undergoing tumor induction, tail tips were taken at
seven weeks and snap frozen in liquid nitrogen for RNA
and DNA. For mice not undergoing tumor induction,
tail, dorsal skin, and other tissues were harvested after
sacrifice by asphyxiation and cervical dislocation at
seven weeks. All mouse experiments were approved by
the University of California at San Francisco Laboratory
Animal Resource Center.
Tumor induction
Chemical carcinogenesis was initiated using the two-stage
DMBA/TPA protocol. In brief, seven-week-old mice were
shaved and treated with 25 μg DMBA in acetone over an
approximately 2-in. squared region on the center of the
back. For the following 20 weeks, 200 μL of 10−4 M TPA
in acetone was applied twice per week to the DMBA-
treated area. Mice were shaved two days prior to the first
TPA treatment for that week. TPA treatments were con-
tinued for 20 weeks.
Genotype, expression, and phenotype measurements
Phenotype measurements
Mice were weighed at seven weeks and values rounded
to the nearest 100th of a gram. Lengths were measured
by first anesthetizing mice and then by measuring the
nasal–anal distance in centimeters rounded to the nearest
tenth. BMI was calculated by taking the weight (in grams)
at seven weeks and dividing by nasal to anal length
squared (in cm).
The resulting phenotype values were mean centered
by sex prior to use in analysis. All distributions were
approximately normal. Litter size was not significantly
correlated with any phenotype.
Tumor burden and carcinogenesis risk
Papillomas were counted every two weeks starting at
the tenth week of TPA administration until the 20th
week. This induction protocol also results in the devel-
opment of carcinomas in a high fraction of mice. Mice
were continually observed for the emergence of carcin-
omas. At carcinoma formation, the date and location
were recorded. The time from DMBA/TPA treatment
start to carcinoma emergence was then used to calcu-
late carcinoma-free survival.
Tumor-bearing mice were sacrificed by asphyxiation
followed by cervical dislocation when carcinoma diam-
eter exceeded 1 cm and/or when the mouse body
condition score began to deteriorate. At sacrifice, dorsal
skin, all tumors, and other tissues were harvested. Tis-
sues were immediately split, with one section fixed in
4 % paraformaldehyde and subsequently embedded in
paraffin for histology, and another section snap frozen
in liquid nitrogen for DNA and RNA extraction.
Genotyping
Genotypes were generated using pre-treatment tail DNA
with a custom panel of TaqMan assays (Life Technologies,
Carlsbad, CA, USA) consisting of 276 markers (Additional
file 1: Table S1) tiling the autosomes and the X
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chromosome at approximately 10 cM spacing. Genotyping
reactions were performed using the WaferGen SmartChip
qPCR system (WaferGen Biosystems, Fremont, CA, USA)
as per manufacturer’s recommendations. Autosomal ge-
notypes were assigned by comparing sample values to
control FVB, SPRET, and F1 samples.
For the X chromosome, genotypes were assigned by
splitting mice by sex, manually identifying outliers, and
defining genotype groups by linear discriminant analysis
using the lda function from the MASS (7.3-33) package
in R [13].
Prior to analysis, mice with high missing genotype rates,
implausible recombination rates, and duplicate samples
were identified and excluded. Additionally, markers
with either low heterozygous or homozygous calls were
excluded, as well as markers with high missing rates, as
described in Broman and Sen [14].
Gene expression
RNA was generated from tail and dorsal skin samples
taken at seven weeks. Tail tissue was frozen in liquid
nitrogen, ground by chilled mortar and pestle, and
suspended in TRIzol. TRIzol RNA extraction was then
performed, followed by purification by Qiagen kit. RIN
values were calculated by Bioanalyzer and samples with
high quality (greater than six) were used for analysis.
Selected samples were hybridized to an Affymetrix
mouse gene ST 1.1 array. Gene expression values were
calculated in R using the oligo package (1.26.6) [15].
Expression values were normalized at the transcript
level via the RMA algorithm using a set of custom set
of probe annotations. This custom set of annotations
was designed to account for the high quantity of se-
quence dissimilarities between FVB and SPRET mice
by removing any probe with a known single nucleotide
polymorphism (SNP) between these two strains from
the annotation. This method has recently been published
[16]. Expression levels were then normalized across plates
via the COMBAT method [17].
Bioinformatics analysis
QTL analysis
QTL analysis was performed using the scanone function
from the R package qtl (version 1.27-10) [18]. Extended
Haley-Knott regression was initially performed to iden-
tify single QTL for each phenotype in a single combined
dataset consisting of both sexes. Significance was evalu-
ated by comparing observed values to those obtained in
1000 random permutations for autosomes and 27,000
for the X chromosome.
Initial investigations compared the results of assessing
each phenotype with no covariates, with sex as an additive
covariate, and again as an interactive covariate. Including
sex as an additive covariate was uninformative in all cases,
owing to the phenotypes being mean-centered by sex.
There was sufficient evidence to conclude that sex
interacted meaningfully with genotype in several cases
for BMI, and as a result sex was included as an inter-
active covariate for the autosomes for BMI. Sex was not
included as a covariate for weight or length. LOD peak
thresholds were defined by taking the 95 % Bayesian
credible interval for each peak [14].
The existence of multiple loci and interactions between
single loci was evaluated by using the scantwo function
from qtl limited to chromosomes previously identified as
having a significant QTL. The results were then compared
against permutation thresholds to establish the existence
of multiple loci in individual linkage peaks, as well as any
cis or trans interactions between autosomal QTL. There
was no evidence of any significant interactions between
QTL, although some peaks were determined to be com-
prised of several independent signals.
In order to refine further the candidate QTL, we utilized
the refineqtl function from the qtl package. This function
attempts to maximize the LOD score by shifting the loca-
tion of candidate loci in a combined model.
To assess the significance of sex:genotype interactions
at individual QTL, we performed linear modeling in-
corporating marker genotype, sex, and the sex:genotype
interaction term as predictors of phenotype values.
Significance was evaluated by ANOVA with α = 0.05.
Candidate gene identification
Candidate genes associated with each QTL were identi-
fied by two strategies; first, by finding all genes located
within the QTL peak that also possessed at least one
non-synonymous SNP between FVB and SPRET animals;
and second, by finding all genes with an expression QTL
(eQTL) peak within the QTL region.
To identify genes with a SNP in a QTL, we used the
markers closest to the QTL boundaries to define the
physical boundaries of the QTL. Using these regions,
we identified sites at which FVB and SPRET were non-
equivalent in the GRCm38 (REL-1303) database of
SNPs and indels available from the Sanger Institute
(ftp://ftp-mouse.sanger.ac.uk/). We then annotated these
sites with Annovar and excluded synonymous and non-
coding sites [19]. The list of selected SNPs included any
that resulted in one of the following: non-synonymous
substitution, nonsense substitution, frameshift dele-
tions, frameshift insertions, and variants in a splice site.
Any gene with one or more of these types of polymor-
phisms was considered to be a candidate by sequence
analysis.
To identify genes with significant cis or trans eQTL as-
sociated with the phenotype linked QTL, we performed
differential expression analysis using the siggenes package
(1.36.0) in R [20]. We calculated the d statistic for all
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genes relative to the marker closest to the QTL peak. For
markers on the X chromosome we treated male and
female genotypes as distinct (AA/AB for females, and AY/
BY for males). Multiple test correction was applied by
controlling the false discovery rate, with α approximately
equal to 0.05.
Genes selected by differential expression analysis were
then subjected to selection by eQTL peak analysis. For
all genes that were significantly differentially expressed,
we performed an eQTL analysis using the scanone func-
tion from the qtl package in R to identify the maximum
LOD peak for that gene. If the Bayes 95 % credible inter-
val for the eQTL overlapped with the 95 % credible
interval for the associated phenotype QTL, and if the
LOD score for the linkage peak was greater than or
equal to three, the gene was considered to be a candi-
date by differential expression analysis.
Phenotype and gene expression analysis
We used the limma package (3.18.13) [21] to compare
the expression levels of genes in the union of the two
candidate gene sets (sequence and differential expres-
sion) to the respective phenotype values. We modeled
gene expression values by phenotype values and ad-
justed for multiple tests by controlling the false discov-
ery rate, with α approximately equal to 0.05. This was
performed independently in males, females, and a com-
bined dataset.
Genes with p values below the FDR were then adjusted
for marker genotypes and compared to phenotype
values. Genes that remained significant (α = 0.05) after
adjusting for marker genotype were considered signifi-
cant. For genes selected by eQTL analysis, we also evalu-
ated the congruency of the QTL-phenotype/gene-eQTL/
gene-phenotype relationships. In all cases except one, the
QTL-phenotype/gene-eQTL/gene-phenotype was congru-
ent with expectations.
Genes which were significant after accounting for
marker genotype and which were congruent with ex-
pected directionality (if it was possible to evaluate this)
were considered hits for each respective phenotype/sex
combination.
Gene expression correlation network analysis
Gene expression values were correlated by Spearman’s
method, and significance thresholds were estimated calcu-
lating the 5 % genome wide error rate (GWER) [22, 23].
Significance thresholds were calculated in male and female
samples independently.
The Panx3 neighborhood was defined as those probes
correlated with Panx3 with rho values over the 5 %
GWER (first-degree neighbors), as well as all significant
correlations of the set of first-degree neighbors.
Gene ontology enrichment analysis was accomplished
by comparing genes in the Panx3 neighborhood with all
annotated probes using the R package topGO (2.14.0) [24].
Gene expression correlation network visualization
Gene co-expression networks were visualized in Cytoscape
(3.2.1; http://www.cytoscape.org/) using default parameters
and organic layout. Some node positions were then manu-
ally adjusted to improve interpretability.
Panx inhibition and qPCR gene expression analysis
Forty female FVB mice aged seven weeks were broken
into four treatment groups consisting of ten animals
each. The mice were shaved across a two-in. square area
on the back two days prior to treatment. The four
groups received intraperitoneal (IP) injections of either
0.9 % saline or 100 mg/kg carbenoxolone (CBX; Sigma
Aldrich C4790) dissolved in 0.9 % saline.
Thirty minutes after IP injections, mice were treated
with either 200 μL of acetone or 200 μL of 10−4 M TPA
in acetone across the shaved dorsal skin surface. At 24 h
post topical treatment, mice were sacrificed and a sec-
tion of dorsal skin snap frozen in liquid nitrogen and a
section fixed in formalin for histology. RNA was then
extracted using Direct-zol RNA MiniPreps (Zymogen;
R2050).
Using this RNA, we then probed for the expression
levels of Il6 and Il1b (selected based on the observation
that these genes were the most differentially expressed
interleukins in a cohort of FVB mice treated with TPA)
using TaqMan probes purchased from Life Technologies
(Mm00446190_m1 for Il6; Mm00434228_m1 for Il1b).
Beta-actin was included as a control probe.
Expression values were calculated by comparing the Ct
values observed for Il6 and Il1b to that of Beta-actin and
compared to delta Ct values in the saline/acetone treated
mice (via the delta-delta Ct method; http://www.biocon-
ductor.org/packages/release/bioc/vignettes/ddCt/inst/doc/
rtPCR.pdf). These values were then assessed for statistical
significance by t test comparing the delta-delta Ct values
between control and treatment groups. For plotting this
was then converted into relative starting quantities by the
following equation: 2^(−x), where x is the delta-delta Ct
value.
Skin samples were fixed in 4 % PFA, dehydrated, and
embedded in paraffin. Sections of 5 μm were mounted on
slides and stained with hematoxylin and eosin (H&E). The
degree of inflammation was evaluated by assessing the
epidermal thickness and dermal nuclei abundance. Overall
levels of inflammation were scored by a researcher blinded
to sample labels on a scale of 0–3, with 0 corresponding
to no inflammation and 3 to a high degree of inflamma-
tion. Differences between treatment groups were tested
for significance by Fisher’s exact test.
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Statistical analysis
All statistical analyses were performed in R (3.0.2).
Correlation analysis was performed using Spearman’s
method. Differences between groups were evaluated by
the Mann–Whitney U test. Linear regression signifi-
cance was evaluated by ANOVA. The significance of
phenotype-phenotype interactions was evaluated by in-
corporating both terms into a linear model and evalu-
ating the significance of the interaction term.
Survival analysis was performed using the survival
package (2.37-4) [25]. Cox proportional hazards model-
ing was performed on carcinoma-free survival data. Sig-
nificance was evaluated by log-rank test.
Results
Increased weight and BMI are associated with increased
papilloma burden
In order to evaluate the relationship between pre-treatment
physiological parameters and carcinogenesis, we com-
pared pre-treatment BMI, weight, and length to papil-
loma burden in two independent skin carcinogenesis
cohorts. These cohorts were generated from a population
of interspecific Mus spretus (SPRET/Ei) and Mus musculus
(FVB/N) backcrossed mice. F1 progeny were generated by
crossing male SPRET mice with female FVB animals, and
the backcross population was generated by crossing female
F1 mice with male FVB. The resulting population (FVBBX
mice) was then phenotyped (see Methods) and subjected
to two-stage chemical carcinogenesis (Fig. 1a).
The first cohort (hereafter Cohort 1) consisted of 141
mice, 139 of which had whole-genome genotyping data
available. The second cohort of mice (Cohort 2) consisted
of 237 mice, 235 of which had genotyping data available
(Table 1). In both cohorts there were approximately as
many female as male mice (Table 1). There were no
significant differences in papilloma burden, BMI, or
carcinoma risk between the two datasets. Additionally,
sex was not significantly associated with papilloma bur-
den or the risk of developing a carcinoma.
In these cohorts, BMI and weight, but not length,
were significantly positively correlated with papilloma
burden (Fig. 1b). In a combined analysis, BMI was posi-
tively correlated to papilloma burden (p < 1e-5, rho =
0.25). This relationship appears to be driven primarily
by male mice, which show a correlation p value < 1 e-7
and a rho of 0.38 (Fig. 1b). BMI was not significantly cor-
related with papilloma burden in female mice (Additional
file 2: Figure S1). Similar results were observed for weight,
which showed a significant positive correlation with papil-
loma burden in male mice (rho = 0.33; p < 1e-5), and no
correlation in female mice. Separating the two cohorts
showed a consistent level of correlation between BMI and
papilloma burden for male mice in both cohorts: p < 1e-3
and rho = 0.4 for Cohort 1 male mice and p < 1e-3 with
rho = 0.34 for Cohort 2 male mice.
Next, we compared papilloma burden between mice
with extreme BMI values, defined as mice with BMIs in
the top or bottom quartile of values for each sex. Com-
paring papilloma burden between mice with high and
low BMI uncovered a significant increase in burden for
male mice with high BMI (p < 1e-4; in this cohort high
was defined as BMI greater than 0.29 and low as BMI
less than 0.24), and no difference in female mice (Fig. 1c).
This increase was consistent between the two cohorts
(p < 1e-4 and p = 0.015 for cohorts 1 and 2, respect-
ively). Male mice with weights in the highest quartile of
values also showed a similar increase in papilloma burden
(p < 1e-4 and p < 0.001 for cohorts 1 and 2, respectively).
This may suggest that the effect of increased weight
and BMI on papilloma burden is attenuated, if not
absent altogether, in female mice. In support of this, a
linear model predicting papilloma burden by either BMI
or weight and sex demonstrated the existence of a
significant interaction between the two terms (p = 0.019
for the interaction between BMI and sex; p = 0.027 for
weight and sex).
Increased BMI is associated with carcinoma development
In addition to the influence of BMI on papilloma burden,
we also investigated the relationship between BMI and
carcinoma formation. For this investigation both cohorts
were merged and treated as a single dataset in order to
maximize statistical power.
Using this set of 378 mice, of which 262 developed a
carcinoma, we found that BMI was significantly associ-
ated with increased risk of carcinoma development in
male mice (p < 1e-3), but not in female mice. Male mice
with high BMIs (as defined as the top 25 % of BMI
values) were at approximately 2.36-fold increased risk
of developing a carcinoma relative to mice with the
25 % lowest (p = 0.0013; 95 % CI for risk ratio: 1.40–
4.00; Fig. 1d). Weight values were also associated with
carcinoma-free survival, albeit at an attenuated level. In
male mice weight predicted carcinoma-free survival
with a p value = 0.026. In female mice there was no sig-
nificant association between weight and carcinoma-free
survival. Length was not a significant predictor for ei-
ther sex (p > 0.05).
Carcinoma risk is defined both by the formation of
benign lesions, as well as the progression of benign
lesions to malignancy. To assess whether the effect of
BMI on carcinoma risk was due to progression or initi-
ation, we modeled carcinoma risk by both BMI and
papilloma burden. In this model we found that BMI
was not a significant predictor (p > 0.05), suggesting
that the primary effect of BMI on tumorigenesis is to


























































































































































































Fig. 1 (See legend on next page.)
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increase the number of early stage tumors rather than
to induce tumor progression.
Multiple overlapping genomic loci influence weight and
BMI
FVB and SPRET mice vary significantly in average
weight and adiposity, with FVB mice typically weighing
more and having a lower percentage of body mass at-
tributable to fat [26]. As these phenotypes are known to
be genetically influenced, we next wanted to identify the
genetic factors influencing BMI, weight, and length in
the backcross population. To accomplish this, we per-
formed QTL mapping using mice from both cohorts (see
“Methods”). We were able to identify multiple significant
loci for each phenotype (Fig. 2). For BMI, eight total loci
were identified (on chromosomes 3, 4, 6, 9, 10, 11, 12, and
X). For both weight and length, four loci were identified
(for weight: chromosomes 4, 10, 11, X; for length chromo-
somes 7, 10, 11, and X). The effect of the most significant
autosomal QTL for weight, length, and BMI is depicted in
Additional file 2: Figure S2.
We were able to determine that the weight QTL on
chromosome 10 was composed of two distinct and op-
posite in orientation QTL, one distal and one proximal
(Additional file 2: Figure S3). For both the weight and
length QTL on chromosome X, we determined that the
QTL comprised two distinct, but congruent in orienta-
tion, QTL. The final locations, LOD scores, and r2
values for all significant peaks are listed in Table 2, and
the QTL regions are depicted graphically in Fig. 3a. In
the majority of cases (14 out of 19), the SPRET allele
conferred increased phenotype values, with the FVB al-
lele associated with reduced values (Fig. 3a).
Using linear models structured to permit an inter-
action between sex and marker genotype, we were able
to identify two QTL with significant interactions with
sex. BMI_3 and BMI_9, on chromosomes 3 and 9, re-
spectively, both showed significant interactions between
sex and genotype (BMI_3 p interaction = 0.020; BMI_9
p interaction = 0.038). BMI_3 showed a striking increase
in BMI for heterozygous female mice relative to homozy-
gous females, but no difference in male mice (Additional
file 2: Figure S4). Conversely, heterozygous males at
BMI_9 had approximately 8 % higher BMI than their
homozygous counterparts, while female mice showed
no difference between heterozygous and homozygous
mice (Additional file 2: Figure S4). Two other loci, BMI_4
and BMI_11, were also suggestive but non-significant
(Additional file 2: Table S2).
BMI QTL peaks are associated with tumor burden in
males
To evaluate the relationship between BMI linked QTL
and tumorigenesis we used QTL genotypes as predictors
of papilloma burden. This analysis was performed in a
combined dataset, as well as sex-specific datasets.
We found that loci that influence BMI tend to also in-
fluence papilloma burden in males. Of the set of eight
BMI QTL, six were significantly associated with papilloma
burden in males. Of these six, four were not significantly
Table 1 Mouse totals by cohort and sex. Values in parenthesis represent the standard deviation












Cohort 1 total 141 23.79 (4.85) 9.66 (0.58) 0.25 (0.04) 90 139 109
Cohort 1 males 78 26.13 (4.56) 9.85 (0.57) 0.27 (0.03) 45 76 59
Cohort 1 females 63 20.88 (3.41) 9.43 (0.52) 0.23 (0.03) 45 63 50
Cohort 2 total 237 24.05 (5.57) 9.60 (0.56) 0.26 (0.04) 172 235 0
Cohort 2 males 116 26.53 (5.53) 9.82 (0.53) 0.27 (0.03) 87 114 0
Cohort 2 females 121 21.68 (4.48) 9.39 (0.51) 0.24 (0.04) 85 121 0
(See figure on previous page.)
Fig. 1 BMI and carcinogenesis are strongly associated in male mice. a Schematic of cross-generation and tumor induction. b Correlation heatmap
between pre-treatment phenotype values and tumor burden measured at multiple tumor timepoints. Negative log10 of the p value for Spearman’s
rank-order correlation is plotted for male mice, female mice, and the combined dataset. c Tumor burden is higher in male mice with higher BMI and
weight values. Papilloma burden at 20 weeks was compared between mice in the highest and lowest quartile for each phenotype. Bars represent the
95 % CI for the mean for mice in the highest quartile (blue) and lowest quartile (orange) for each sex. Female and male mice are plotted separately on
the right and left halves, respectively. All differences between phenotype groups in males are significant and no differences in females are
significant. d Survival curve for mice with high BMI and low BMI values split by sex. Kaplan–Meier plots for carcinoma-free survival mice with
the highest 25 % of BMI values (orange) and lowest 25 % (blue). BMI group is a significant predictor of carcinoma risk in male mice with p = 0.0013 by
log-rank test. There is no significant difference in females
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associated with papilloma burden in female mice. There
were two BMI QTL that were significantly associated
with papilloma burden in all datasets (Additional file 2:
Table S3).
In order to evaluate whether or not the relationship be-
tween these markers was congruent with the expectation
of increased BMI positively influencing carcinogenesis
risk, we assessed whether the high-BMI allele was also the
high-papilloma burden allele. This was true in all cases
except for BMI_3. The strongest and most consistent rela-
tionship between BMI QTL genotype and papilloma
burden in both males and females was found at BMI_12
in a region containing a previously mapped papilloma
susceptibility locus (Skts5) [10]. Of the remaining QTL,
four out of six (BMI_4, BMI_6, BMI_9, and BMI_11) were
associated with significant differences in papilloma burden
Table 2 QTL locations and variance explained
QTL name Chromosome Position (mb) Left bound (mb) Right bound (mb) LOD score Variance explained
BMI_3 3 96 41 116 3.81 0.031
BMI_4 4 126 111 126 5.05 0.055
BMI_6 6 80 25 80 3.81 0.024
BMI_9 9 42 25 69 3.88 0.027
BMI_10 10 15 13 25 6 0.059
BMI_11 11 51 36 85 3.89 0.027
BMI_12 12 8 8 40 3.58 0.039
BMI_X X 36 36 78 6.76 0.098
WEI_4 4 112 91 148 3.51 0.044
WEI_10_PROX 10 15 5 44 4.74 0.028
WEI_10_DIST 10 107 60 121 3.58 0.052
WEI_11 11 51 4 89 5.31 0.063
WEI_X_PROX X 36 12 60 9.13 0.194
WEI_X_DIST X 120 95 151 4.35 0.137
LEN_7 7 66 52 126 3.18 0.033
LEN_10 10 107 91 121 4.18 0.07
LEN_11 11 11 4 95 4.62 0.06
LEN_X_PROX X 48 12 60 5.61 0.174
LEN_X_DIST X 120 95 151 5.62 0.151
QTL names were defined by combining the phenotype, the chromosome, and if applicable the relative location on the chromosome

























Fig. 2 Genome-wide linkage plots for pre-treatment phenotypes by sex. Chromosomes are arranged head-to-tail on the x-axis, LOD scores are
plotted on the y-axis. LOD scores were computed in all samples, as well as in males only (blue) and females only (red). Significance thresholds for
the combined data are indicated by the dashed horizontal red line. The X chromosomes were omitted for this plot
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by marker genotype in male mice. None of these QTL
were significantly associated with papilloma burden in
female mice.
BMI_3 overlaps a papilloma QTL and confounds the
relationship between BMI and tumorigenesis in female
mice
In an effort to understand what differentiates the rela-
tionship between BMI and carcinogenesis in male and
female mice, we further explored the female-specific
QTL on chromosome 3 (BMI_3). This QTL, which
extends from 21 cM/41 mb to 59 cM/116 mb, overlaps
a previously identified tumor susceptibility QTL [8, 12].
Congruent with this observation, heterozygosity at this
locus was associated with a significant decrease in pap-
illoma burden in both males and females (p = 0.0012 in
females and p = 0.0014 for males).
Conversely, while the effect of this QTL on papilloma
burden was not different between the sexes, the effect
on BMI was only present in females (p < 2e-5 in females,
p = 0.44 in males). Importantly, heterozygous females
were heavier than their homozygous counterparts. The
combined effect of the BMI_3 QTL (increasing BMI in



































































Fig. 3 QTL for pre-treatment phenotypes and candidate BMI genes. a QTL regions by phenotype. Shaded bounds depict the QTL regions identi-
fied as significant for each phenotype, with the colored bar displaying the QTL region maximum. Marker locations are indicated as gray bars across
the chromosome. The level of shading indicates QTL directionality, with lightly shaded regions corresponding to QTL with heterozygous mice hav-
ing lower mean phenotype values and heavily shaded regions corresponding to QTL with heterozygous mice having higher mean phenotype
values. b BMI associated genes. Candidate genes that were significantly associated with BMI are plotted, along with their location on the chromo-
some. QTL regions are plotted in green, with the QTL peak as a thick dark line. Shading is assigned as in panel A
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on chromosome 3 (decreasing papilloma burden in het-
erozygous mice) severely confounds the relationship be-
tween BMI and papilloma burden for females in this
dataset.
After taking genotype at this QTL into account, there
is evidence for a modest but significant positive correl-
ation between BMI and papilloma burden for female
mice (p < 0.01; rho = 0.19). There was no significant as-
sociation with carcinoma risk after adjusting for BMI_3
marker genotype, suggesting that while there is a rela-
tionship between BMI and tumorigenesis in females in
this dataset, it is attenuated relative to males.
In summary, we found that the relationship between
papilloma burden and BMI is confounded in female mice
by the existence of a female-specific BMI QTL that over-
laps a previously described papilloma QTL. The result of
this confounding is to mask the existence of a modest
positive association between BMI and papilloma burden
in female mice.
Network analysis implicates Panx3 as a candidate lipid
metabolism gene
QTL analysis can identify genomic regions linked to a
phenotype, but this approach is limited by the low gen-
etic resolution inherent in mouse backcross or inter-
cross studies. Gene expression analysis can contribute
substantially to identification of candidate genes or
pathways that influence individual mouse phenotypes
[22, 27–30]. In an attempt to identify the genetic ele-
ments responsible for the observed linkage to BMI, we
performed gene expression correlation network analysis
using a total of 110 pre-treatment tail skin samples
from FVBBX mice. We selected genes inside each QTL
region, in addition to those genes with significant eQTL
linked to the BMI QTL. Using these genes as a starting
point, we then identified genes with pre-treatment
expression values significantly correlated with BMI (see
“Methods”).
Analyzing gene expression values in this way allowed
us to nominate several candidate genes associated with
BMI (Fig. 3b; Additional file 2: Table S4). This set of
genes includes the X-linked Cul4b, which has previously
been associated with syndromic obesity in humans [31],
and Man2c1 which has been associated with a gonadal
fat pad QTL on chromosome 9 in mice [32]. The set as
a whole, however, was not significantly enriched for any
specific function as assessed by gene ontology analysis.
As a strategy to gain additional insight into potentially
novel associations between these candidate genes and
adiposity, we performed gene expression correlation
network analysis in pre-treatment mouse tail RNA. Briefly,
each BMI-associated gene was used as a seed to propagate
a gene co-expression network. The co-expression network
consisted of the seed gene, genes significantly correlated
to the seed gene (first degree neighbor genes), and
genes significantly correlated to first degree neighbors.
Co-expression networks were then analyzed for enrich-
ment by gene ontology analysis (see “Methods”).
The results of this analysis revealed a strong associ-
ation between the Panx3 gene and lipid metabolism
genes. While other candidate genes have plausible rela-
tionships to BMI, none were members of clearly
defined BMI-related gene co-expression networks. This
led us to pursue Panx3 as our primary candidate for
further analysis. Panx3 is a recently characterized inte-
gral membrane protein in the Pannexin family. This
gene has previously described roles in keratinocyte dif-
ferentiation and carcinogenesis, bone morphogenesis,
WNT signaling, and monocyte recruitment [33–36].
Panx3 expression was significantly correlated with BMI
in males (p < 0.01; rho = 0.34) and not correlated in female
mice (p > 0.05). Male mice in the upper quartile of BMI
values mice had approximately 50 % higher expression
than the lowest quartile (8.36 versus 7.99; p < 0.01). In
addition, the gene expression correlation network sur-
rounding Panx3 was significantly enriched in genes asso-
ciated with a variety of lipid phenotypes, including lipid
metabolic process (GO:0006629; p < 1e-4), long-chain
fatty acid transport (GO:0015909; p < 1e-4), and lipid
storage (GO:0019915; p < 1e-3; Fig. 4). This enrichment
was driven by numerous genes with established lipid
metabolism annotations, including Pparg, Fa2h, Mgll, and
Dgat1.
To assess the reproducibility of the Panx3 correlation
network, we analyzed gene expression data obtained
from an independently derived cohort of FVBBX mice.
This dataset consisted of RNA microarray data from 49
dorsal and 48 tail skins isolated from male mice taken
between six and eight weeks. Using these data, we were
able to confirm the reproducibility of the Panx3 neigh-
borhood to a strikingly high degree. In tail skins, the
Panx3 neighborhood in the validation cohort contained
31 out of 32 of the originally associated genes and in
dorsal skins it contained 27 out of 32. In both cases the
validation neighborhood was significantly enriched for
the same type of lipid metabolism phenotypes as previ-
ously observed (lipid metabolic process GO:0006629;
dorsal p < 1e-10, tail p < 1e-6: lipid storage GO:0019915;
dorsal p < 1e-4, tail p < 1e-5). Although the association
between Panx3 and BMI was seen predominantly in
male mice in this cohort, the linkage of Panx3 expres-
sion to the lipid metabolism network was significant for
both males and females (Additional file 2: Table S4).
Analyzing the sequence of the Panx3 gene revealed the
existence of three non-synonymous SNPs between the
FVB and SPRET strains (Additional file 2: Table S6). These
SNPs were not predicted to be deleterious to protein func-
tion (as assessed by PROVEAN; http://provean.jcvi.org),
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but are in close proximity to predicted phosphorylation
sites [37]. In the case of the G500C/S167T polymorph-
ism, the SNP occurs at the exact site of predicted
phosphorylation.
Panx3 expression is positively associated with tumor risk
In order to evaluate the relationship between Panx3
and tumorigenesis, we assessed whether pre-treatment
levels of Panx3 were associated with tumor development
or progression. Panx3 expression in pre-treatment tail
skin was positively correlated with papilloma burden
(p = 0.032, rho = 0.28; Additional file 2: Figure S5A), as
well as with carcinoma risk in males (p = 0.012; Additional
file 2: Figure S5B), indicating that elevated Panx3 levels
are associated with both early and late stages of tumor
development. There was no significant relationship be-
tween Panx3 expression and papilloma burden in female
mice (p > 0.05, rho = −0.09; Additional file 2: Figure S5A)
and Panx3 expression was not a significant predictor of
carcinoma risk for female mice (p > 0.05; Additional file 2:
Figure S5C).
Panx3 expression has previously been reported to
undergo downregulation during carcinogenesis in hu-
man tumors [34]. Using a previously generated cohort
of mouse tail skin, benign papillomas, and malignant car-
cinomas, we assessed the expression levels of Panx3 [30].
Congruent with human data, Panx3 expression was
markedly reduced in tumors, with carcinomas showing
no significant expression of Panx3 (Fig. 5a; p < 1e-10).
Expression levels in papillomas were reduced, but less
consistently than carcinomas (Fig. 5a; p < 3e-5). The
positive association between tumor risk and Panx3
levels in normal skin, but reduced Panx3 expression in
papillomas and carcinomas, supports the interpretation
that the primary role of Panx3 during tumor develop-
ment is in influencing tumor susceptibility rather than
tumor maintenance.
Panx inhibition increases inflammation following TPA
treatment
Among the functions attributed to members of the
Pannexin family, particularly Panx1 and Panx3, are
roles in innate immune cell recruitment and inflamma-
tion [38–40]. Since inflammation is also known to play
a critical, if complex, role in skin tumor development,
we speculated that inhibition of Pannexin function may
perturb inflammatory processes and thus influence






























Fig. 4 The Panx3 gene expression correlation neighborhood. The Panx3 gene expression correlation neighborhood is plotted. Genes are
represented as nodes and significant correlations are plotted as edges. Nodes with GO annotations to lipid metabolic process (GO:0006629) are
shown in dark blue and genes with other connections to adiposity are shown in light blue. Panx3 is plotted in red. All other genes are plotted
in white
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In order to test this hypothesis, we assessed the effect
of small molecule inhibitors of Panx function (both
Panx1 and Panx3) on inflammatory cytokine expression
following TPA treatment of mouse skin. To accomplish
this, we used the Panx inhibitor carbenoxolone (CBX),
which acts as an inhibitor of Pannexin channels [41–43].
Mice were pre-treated by intraperitoneal injection of CBX
prior to the induction of inflammation with TPA. In mice
treated with both CBX and TPA, the expression levels of
the inflammatory interleukins Il6 and Il1b were dramatic-
ally elevated (Fig. 5b) compared to control animals treated
with either CBX alone or TPA alone. While there was no
change in either Il6 or Il1b expression following CBX
treatment alone (p > 0.05 for both markers) treatment
Fig. 5 Panx3 expression during tumorigenesis and the effect of Panx inhibitors on inflammatory interleukin expression. a Panx3 expression is
plotted by tissue. Expression levels are depicted by box-and-whiskers plots, with values lying further than 1.5 times the interquartile range
plotted as dots. Comparisons between all tissues are significant; Tail vs. Papillomas, p < 1e-10; Tail vs. Carcinomas p < 1e-10; Papillomas vs.
Carcinomas, p < 3e-5. b Interleukin 6 (Il6) and interleukin 1b (Il1b) transcript abundances relative to control mice are plotted following TPA
and/or carbenoxolone (CBX) treatment. Mice were treated with IP saline or 100 mg/kg CBX, followed by 200 μL topical acetone or TPA in
acetone. Control mice were defined as mice treated with IP saline and topical acetone. Tissues were harvested 24 h after topical treatment
with TPA or acetone. Expression levels are shown as ddCt values transformed to relative transcript abundances. Bars represent the 95 % CI
around the mean, with the mean plotted as a square. c Tissue histology following TPA and/or CBX treatment. Representative skin samples
from mice treated as described above are displayed for each treatment group. Arrows denote high areas of infiltration in representative
samples from mice treated with the combination of TPA and CBX, as assessed by an observer blinded to sample IDs. Several areas showing
representative levels of infiltrating cells are enlarged for the TPA/acetone and TPA/CBX treated samples
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with TPA, as expected, significantly elevated the expres-
sion levels of both markers (p < 1e-5 for Il6; p = 0.0232
for Il1b), but not to the same extent as the combined
treatment (p = 0.0232 for Il6; p = 0.00288 for Il1b). In
agreement with these results, histological examination
of the skin morphology in treated samples supported
these claims, with CBX and TPA treated samples scor-
ing significantly higher for markers of inflammation
(infiltration into the upper dermis and epidermis) than
TPA alone (p = 0.005; Fig. 5c). There was no difference
between saline and CBX treated samples in the absence
of TPA (p > 0.05). These results demonstrated that in-
hibition of Pannexin function can exacerbate the innate
immune response to treatment with the tumor pro-
moter TPA and could explain the observed genetic
linkage between Panx3 levels and tumor burden.
Discussion
Genetic relationships between BMI and cancer
The relationship between obesity and cancer has been a
topic of intense scrutiny in the scientific community for
well over a decade. In the intervening period since the first
large-scale prospective investigation of this association
and today, a myriad hypotheses have been proposed to ac-
count for this strong positive correlation [4–6]. However,
due to the complexities intrinsic to both phenotypes, dir-
ectly testing these hypotheses has proven challenging.
In this work we have employed a mouse model that is
dependent on exposure to exogenous carcinogens and
tumor promoters to mimic the environmental influence
on cancer development. In addition, our protocol in-
volves crosses between highly divergent mouse species
to replicate the genetic heterogeneity in human popula-
tions [44]. The combination of these two factors (genetic
heterogeneity and carcinogen induction in the absence
of engineered tumor susceptibility) offered us a unique
opportunity to study the interplay between BMI and
cancer development in a system that more closely reca-
pitulates the human condition.
Our results have confirmed the location of several
previously described BMI and adiposity QTL, as well as
described the existence of two novel loci. Our loci on
chromosomes 3, 4, 9, 10, 11, and X appear to overlap
previously described loci [45–56]. In the case of the
QTL on chromosome 6 and chromosome 12, there did
not appear to be an overlapping previously described
BMI-associated QTL, suggesting these sites may be
novel.
Panx3 is in a lipid metabolism network associated with
BMI
In this work we have also identified a potential role for
Panx3, a member of the recently described Pannexin
gene family, in both BMI and cancer susceptibility. This
gene family consists of three members (Panx1–3) in
both rodents and humans [57]. The Pannexin genes
have been associated with a variety of functions, including
keratinocyte differentiation, wound healing, carcinogenesis,
apoptosis, monocyte recruitment, inflammation, and osteo-
blast differentiation [34–36, 58–60]. Panx3 and Panx1 are
known to work in conjunction with one another, both by
directly interacting at the protein level as well as by coordi-
nated gene expression regulation [40, 59].
Currently, there are no published functional links be-
tween Panx3 activity and lipid metabolism. However,
several key observations support the existence of this
relationship. First, previous work from this laboratory
has tied Panx3 expression to adipocyte signaling and
adiposity [61]. In this study we used gene expression
network analysis of normal skin from a separate popula-
tion of F1 backcross mice to predict, and subsequently
verify, a relationship between the protein kinase Hipk2
and adipocyte signaling and differentiation [61]. The ex-
pression network identified in this work also contained
Panx3, suggesting that this gene may also contribute to
these phenotypes. Network analysis has previously been
applied to the identification of candidate genes involved
in BMI [62, 63], demonstrating that this technique is
well-suited to exploring the relationship between Panx3
and BMI.
Further evidence for a role for Pannexins in lipid metab-
olism came from recent analysis of a Panx1 knockout
mouse, which acquired significantly increased amounts of
subcutaneous adipose tissue, accompanied by a dramatic
elevation of Panx3 expression. These data, together with
the observation of increased Panx3 expression in mice fed
a high-fat diet [35] strongly support the hypothesis that
Panx3 signaling is associated with increased adiposity [59]
and consequently BMI. Additional observations have
implicated Panx3 in the persistent disseminated inflam-
mation and metabolic syndrome associated with obesity
[35]. Finally, in humans the genomic region containing
PANX3 has been previously associated with the devel-
opment of obesity, as well as diabetes and serum adipo-
nectin concentrations [64–67].
Although it is possible that Panx3 influences adiposity
through direct expression in skin adipocytes, an alterna-
tive explanation is that Panx3 is primarily expressed in
keratinocytes, possibly facilitating the important role
played by lipid synthesis in maintenance of skin barrier
function [68]. Indeed, previous studies have detected
Panx3 expression in suprabasal keratinocytes and analysis
of subcutaneous adipocytes from mouse skin showed that
Panx3 is expressed at very low levels in this tissue (data
not shown).
Understanding how lipid metabolism in the skin in-
fluences total BMI may be informed by recent publica-
tions detailing the influence of skin-specific knockouts
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of stearoyl-Coenzyme A desaturase 1 (Scd1) on global me-
tabolism [69]. Skin-specific ablation of Scd1 has dramatic
whole-body effects on energy expenditure and lipid me-
tabolism, rendering these mice profoundly resistant to
obesity induced by a high-fat diet. In addition, these mice
show substantial increases in global energy expenditure.
Interestingly, the expression profile of Panx3 is similar to
Scd1, with strong expression in the sebocytes and liver in
adult mice. The gene expression levels of these two genes
are also significantly correlated in normal FVBBX tail
skins (p < 2e-6; rho = 0.45). It is unclear from the available
data what mechanism links skin-specific expression of
Scd1 to whole-body energy expenditure. However, these
findings raise the possibility that skin-specific Panx3
expression, much like Scd1 expression, may influence
whole-body energy expenditure and metabolism.
Pannexins, inflammation, and tumor susceptibility
Panx3 has been shown to influence monocyte recruitment
directly [35]. By modulating recruitment, it is possible that
Panx3 may influence TPA-induced inflammation. An
additional possibility for how Panx3 could be influencing
tumor development is through its relationship with Panx1.
Panx1 is known to play a major role in inflammation [38],
an essential component of tumor formation using the
DMBA/TPA carcinogenesis model [70]. Panx3 may there-
fore influence susceptibility to tumorigenesis through
modulating the response to inflammation, either alone or
in concert with Panx1. In support of a role for Pannexins
in TPA-mediated inflammation in the skin, treatment
with the Pannexin inhibitor CBX resulted in a dramatic
increase in morphological indications of inflammation
as well as elevation of Il6 and Il1b expression levels.
CBX is known to inhibit other targets, including Con-
nexin proteins. However, TPA is also a potent inhibitor
of Connexin proteins [71–73], suggesting that in this
context the effect of CBX on inflammation was driven
by inhibition of Pannexin proteins. These results dem-
onstrate that Pannexin signaling normally attenuates
acute inflammatory responses in the skin following TPA
treatment.
This conclusion may appear to contradict prior work
demonstrating a positive relationship between Pannexins
and inflammation [35, 74–76], as well as inflammation
and tumor susceptibility [77]. However, interpretation of
these data is complicated by the diverse roles of acute
and chronic inflammatory responses in promoting or
inhibiting skin cancer development. Mice that had
undergone selective breeding for high acute inflamma-
tory responses in the skin were shown to be resistant to
skin carcinogenesis [78]. Similarly, over-expression of
interleukin 1 alpha (Il1a) in skin using a keratin 14-Il1a
transgene conferred complete resistance to the two-
stage DMBA/TPA protocol for tumor development by a
mechanism that was proposed to involve increased neu-
trophil infiltration [79], the phenotype also induced in
the present studies by Pannexin inhibition.
Our results demonstrating increased TPA-induced
infiltration after CBX treatment contrast with those
from alternative assays of inflammation, which showed
an inhibitory effect of CBX [71–73]. Clearly, both tissue
context and the mechanism by which inflammation was
induced must be taken into account in interpreting
these data. TPA is a strong tumor promoting agent
known to disrupt Connexin/gap junction activity [80],
which in turn may feed back to alter Pannexin signaling
[38]. While the details of interactions between Panx1,
Panx3, and inflammation in skin remain to be eluci-
dated, these data provide support for the proposal that
alterations in Panx3 levels and/or signaling contribute
to skin tumor susceptibility through effects on acute in-
flammatory responses.
Effects of sex on BMI and tumor burden
In our study we have observed a profound dichotomy
between the sexes. In male mice, elevated BMI is
strongly and positively associated with increased tumor
burden and carcinoma risk. However, in females, there
was no such relationship. A significant complication of
this finding is the relationship between BMI_3 and pap-
illoma burden. This BMI QTL overlaps with a previ-
ously described papilloma QTL, which happens to have
opposite orientation to the BMI QTL. This BMI QTL is
also a female-specific QTL. The net effect of this is to
heavily confound the relationship between BMI and
tumor burden for female mice in this cohort. After
accounting for this relationship, there appears to be an
attenuated, but significant, relationship between BMI
and carcinogenesis in female mice.
This intriguing finding mirrors the state in human
cancer, where a wide variety of cancers show an in-
creased influence of BMI on risk in males relative to fe-
males. In a recent study involving over five million
patients in the UK, Bhaskaran et al. assessed the influ-
ence of a variety of covariates on cancer risk [2]. The
authors found that for 17 of the 22 cancers studied,
BMI played a significant role in the risk of develop-
ment. When the authors considered risk independently
between males and females, they found that for all situ-
ations in which there was a significant difference in the
influence of BMI on cancer risk by sex, males were at
elevated risk. These results suggest, in line with our own
observations, that there may exist a global difference in
the relationship between BMI and cancer by sex.
Future studies of this cohort of genetically heteroge-
neous mice employing a more extensive expression data-
set may help in the identification of additional candidate
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genes that will aid our understanding of the complex in-
teractions between sex, obesity, and tumorigenesis.
Conclusions
We have performed a large-scale analysis of the rela-
tionship between BMI and tumorigenesis in a genetic-
ally heterogeneous cohort of mice. The results of this
experiment have demonstrated that, as in humans, these
two phenotypes are highly correlated. Genome-wide link-
age analysis identified several regions associated with BMI
in this cohort, several of which were also associated with
tumor burden.
Further, using a combined approach involving linkage
analysis, gene expression analysis, and gene co-expression
network analysis, we have implicated the Panx3 gene as
simultaneously influencing both phenotypes. In the skin
pre-treatment Panx3 expression levels are correlated with
both BMI and tumor burden. Panx3 is also present in a
well-conserved lipid metabolism network and Pannexin
function attenuates inflammatory signaling. These results
strongly suggest that Panx3 links tumorigenesis and
BMI at the genetic level. Overall, our data show that
the relationship between BMI and tumorigenesis is
highly complex and represents the product of interac-
tions at both the environmental and genetic levels.
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